Author

J. Hansson

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2 Bioengineering· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:proteomics· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Approach:experimental assay· 1 Approach:genetic perturbation / CRISPR· 1 Organism:human· 1

Frequent Co-Authors

A. Azimi· 1 shared A. Paskevicius· 1 shared A. Petri· 1 shared A. S. Rahmanto· 1 shared C. Guibentif· 1 shared C. Ingvar· 1 shared D. Grander· 1 shared D. Sjovall· 1 shared

Activity by Year

2020-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 22 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. Azimi

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Defective ribosome assembly impairs leukemia stem cell function in a murine model of acute myeloid leukemia

D. Sjovall, S. Ghosh, J. Hansson, C. Guibentif, P. Jaako

This study shows defective ribosome assembly reduces leukemia stem cell survival in a murine AML model without affecting normal hematopoietic cells.

bioRxiv · Jan 22, 2023Cancer Biology

Identification of cardiac afterload dynamics from data

H. Pigot, J. Hansson, A. Paskevicius, Q. Liao, T. Sjöberg, S. Steen, K. Soltesz

The paper develops a method to identify continuous-time transfer functions from sampled data and evaluates its performance on cardiac afterload models.

bioRxiv · Mar 31, 2021Bioengineering

PTENP1-AS contributes to BRAF inhibitor resistance and is associated with adverse clinical outcome in stage III melanoma

L. Vidarsdottir, A. Azimi, I. Sigvaldadottir, A. S. Rahmanto, A. Petri, S. Kauppinen, C. Ingvar, G. Jonsson, H. Olsson, M. Frostvik-Stolt, R. Tuominen, O. Sangfelt, K. Pokrovskaja, J. Hansson, D. Grander, , P. Johnsson

This study shows that PTENP1-AS contributes to BRAF inhibitor resistance and is linked to poor clinical outcomes in stage III melanoma.

bioRxiv · May 3, 2020Cancer Biology